Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy

Retina

Volumn 33, Issue 5, 2013, Pages 946-952

  Christoforidis, John B ^a   Williams, Michelle M ^b   Wang, Jillian ^b   Jiang, Angela ^b   Pratt, Cedric ^b   Abdel Rasoul, Mahmoud ^b   Hinkle, George H ^b   Knopp, Michael V ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IODINE 124; RANIBIZUMAB;

ANIMAL EXPERIMENT; ARTICLE; CILIARY DISK; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HALF LIFE TIME; LENSECTOMY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RABBIT; RADIOACTIVITY; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CATARACT EXTRACTION; INTRAVITREAL INJECTIONS; METABOLIC CLEARANCE RATE; MODELS, ANIMAL; RABBITS; VITRECTOMY;

EID: 84877005677     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182753b12     Document Type: Article

References (23)

1. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
2. Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB Jr. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 1985;92:1601-1605.
3. Pearson PA, Hainsworth DP, Ashton P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina. 1993;13:326-330.
4. Mandell BA, Meredith TA, Aguilar E, et al. Effects of inflammation and surgery on amikacin levels in the vitreous cavity. Am J Ophthalmol 1993;115:770-774.
5. Aguilar HE, Meredith TA, el-Massry A, et al. Vancomycin levels after intravitreal injection. Effects inflammation surgery. Retina 1995;15:428-432.
6. Shaarawy A, Meredith TA, Kincaid M, et al. Intraocular injection of ceftazidime. Effects inflammation surgery. Retina 1995; 15:433-438.
7. Christoforidis JB, Carlton MM, Knopp MV, Hinkle GH. PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest Ophthalmol Vis Sci 2011;52:5899-5903.
8. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859.
9. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182.
10. Zou P, Povoski SP, Hall NC, et al. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET)imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: Preliminary results. World J Surg Oncol. 2010; 8:65.
11. Gisladottir S, Loftsson T, Stefansson E. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefes Arch Clin Exp Ophthalmol 2009; 247:1677-1684.
12. Pflugfelder SC, Hernandez E, Fliesler SJ, et al. Intravitreal vancomycin. Arch Ophthalmol 1987;105:831-837.
13. Yanyali A, Aytug B, Horozoglu F, et al. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-126.
14. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-923.
15. Goldenberg DT, Giblin FJ, Cheng M, et al. Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Retina 2011; 31:393-400.
16. Gad Elkareem AM, Willikens B, Stassen JM, de Smet MD. Differential vitreous dye diffusion following microplasmin or plasmin pre-treatment. Curr Eye Res 2010;35:235-241.
17. Hikichi T, Yoshida A, Hasegawa T, et al. Wound healing of scleral self-sealing incision: A comparison of ultrasound biomicroscopy and histology findings. Graefes Arch Clin Exp Ophthalmol 1998;236:775-778.
18. Darlow BA, Ells AL, Gilbert CE, et al. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2011 Dec 30. [Epub ahead of print]
19. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011;31:1877-1884.
20. Gaudreault J, Webb W, Van Hoy M, et al. Pharmacokinetics and retinal distribution of AMD rhufab V2 after intravitreal administration in rabbits. AAPS Pharm Sci 1999;1(suppl 1):3207.
21. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor- in patients with choroidal neovascularization. Ophthalmology 2008;115:1750-1755.
22. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthlamol 2008;146:508-512.
23. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears MI, ed. Pharmacology of the Eye. New York, NY: Springer-Verlag; 1984:19-116.